

## Independent Medical Education Grants

1<sup>st</sup> Jan 2016 – 31<sup>th</sup> Mar 2016

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

| Recipient Name(s) <sup>1</sup>  | Activity Title   | Funding Amount <sup>2</sup> |
|---|--|-----------------------------|
| Admin of the Tulane Educa Fund on behalf of TUHSC CCE                 | 8TH ANNUAL TULANE SYMPOSIUM ON THYROID AND PARATHYROID DISEASES  | 7,500                       |
| AKH Inc Advancing Knowledge and Healthcare                            | 2016 SOUTH BEACH SYMPOSIUM: CLINICAL DERMATOLOGY SYMPOSIUM   | 5,000                       |
| AKH Inc Advancing Knowledge and Healthcare                            | NOVEL MECHANISMS AND ADVANCING THERAPEUTIC PARADIGMS FOR OPTIMIZING LDL-FOCUSED MANAGEMENT AND CV RISK REDUCTION IN THE DIABETIC PATIENT | 336,000                     |
| C-MEducation Resources, LLC   |  | Collaboration <sup>3</sup>  |
| American Academy of Continuing Medical Education, Inc. Spire Learning | INCREASING ACCESS TO KIDNEY TRANSPLANTATION: NOVEL STRATEGIES TO EXPAND LIVING DONATION  | 104,000                     |
| American Association of Clinical Endocrinologists                     | THYROID SESSIONS AT ENDOCRINE UNIVERSITY®: DISEASE MANAGEMENT & TECHNOLOGY SKILLS FOR ENDOCRINOLOGY FELLOWS IN TRAINING                  | 30,000                      |
| American Association of Clinical Endocrinologists                     | NEVADA AACE THYROID CANCER SYMPOSIUM   | 5,000                       |
| American Association of Clinical Endocrinologists Medtelligence, LLC  | LDL-C REDUCTION IN THE PATIENT WITH DIABETES: HOW LOW SHOULD WE GO AND HOW SHOULD WE GET THERE?  | 267,758                     |
|   |  | Collaboration <sup>3</sup>  |
| American College of Cardiology Foundation                             | DYSLIPIDEMIA COMBO-THERAPY: A FRAMEWORK FOR CLINICAL DECISION-MAKING   | 75,000                      |
|   |  | Collaboration <sup>3</sup>  |
| American College of Rheumatology                                      | 2016 ACR RHEUMATOLOGY COURSES  | 150,000                     |
|   |  | Collaboration <sup>3</sup>  |
| American Health Resources, Inc.                                       | EXAMINING THE ROLE OF PCSK9 INHIBITORS IN DYSLIPIDEMIA MANAGEMENT  | 4,200                       |
| American Kidney Fund  | AMERICAN KIDNEY FUND 2016 CLINICAL SCIENTIST IN NEPHROLOGY PROGRAM   | Collaboration <sup>3</sup>  |
|   |  | 75,000                      |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> “Funding Amount” is the amount that the Company funded during Q1, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Jan 2016 – 31<sup>th</sup> Mar 2016

| Recipient Name(s) <sup>1</sup>  | Activity Title  | Funding Amount <sup>2</sup>           |
|---|---|---------------------------------------|
| American Society of Transplant Surgeons   | ASTS 16TH ANNUAL STATE OF THE ART WINTER SYMPOSIUM: LIMITED SUPPLY, INCREASING DEMAND: EXPANDING ORGAN DONATION                           | 50,000                                |
| Annenberg Center for Health Sciences at Eisenhower  | EXPERTS IN RESIDENCE: BRIDGING THE GAP FROM KNOWLEDGE TO PRACTICE IN CASTRATION-RESISTANT PROSTATE CANCER                                 | 110,000                               |
| Association of Black Cardiologists, Inc.  | EVOLVING STRATEGIES FOR CARDIOVASCULAR RISK REDUCTION: BEYOND STATIN THERAPY  | 350,000                               |
| National Association for Continuing Education   |   | Collaboration <sup>3</sup>            |
| Cardiovascular Center of Sarasota Foundation for Research and Florida Medical Association | 12TH ANNUAL CARDIOVASCULAR SYMPOSIUM CARDIOLOGY UPDATE 2016: FROM INTERVENTION TO PREVENTION TIME TO FOCUS ON EARLY CARDIOVASCULAR HEALTH | 5,000                                 |
| Cardio Renal Society of America   | 4th ANNUAL CARDIO-RENAL METABOLIC CONFERENCE  | Collaboration <sup>3</sup><br>6,000   |
| CME Outfitters, LLC   | IMPLEMENTING PERSONALIZED ACTION PLANS FOR PATIENTS WITH ATOPIC DERMATITIS  | 99,867.5                              |
| Consortium of Multiple Sclerosis Centers<br>Nurse Practitioner Alternatives               | CLINICIAN-PATIENT SHARED DECISION MAKING IN MS: AN ESSENTIAL STEP TOWARD BETTER OUTCOMES  | Collaboration <sup>3</sup><br>100,860 |
| Emory University  | EVALUATION OF THE LGMD DIAGNOSTIC TESTING PROGRAM: PROGRAM UPDATES, OPPORTUNITIES AND FUTURE WORK   | 5,850                                 |
| Forefront Collaborative<br>National Lipid Association                                     | CURRENT CONTROVERSIES IN DYSLIPIDEMIA MANAGEMENT: A POINT-COUNTERPOINT DISCUSSION   | 85,000                                |
| Medical Learning Institute, Inc.  | UNDERSTANDING THE EVOLUTION OF MS CARE: OPTIMIZING THERAPEUTIC DECISION MAKING  | Collaboration <sup>3</sup><br>43,186  |
| Medical Learning Institute, Inc.<br>PeerView Institute for Medical Education, Inc.        | PEERVIEW INCLINIC, "MAXIMIZING CARE FOR INDIVIDUALS WITH MULTIPLE SCLEROSIS: THE ROLE OF INTERPROFESSIONAL EDUCATION"                     | 145,000                               |
| Medical Learning Institute, Inc.<br>PeerView Institute for Medical Education, Inc         | PEERVIEW LIVE, "DISRUPTING DISEASE WORSENING IN PATIENTS WITH MS: HOW CAN WE HARNESS THE FULL POTENTIAL OF AVAILABLE DISEASE-MODIFYING    | 296,820                               |
| Med-IQ, LLC   | WHEN INSULIN ALONE ISN'T THE ANSWER: A FOCUSED LOOK AT COMBINING BASAL INSULIN AND GLP-1 RECEPTOR AGONISTS                                | 257,768                               |
| Med-IQ, LLC   | HOW EARLY IS EARLY? WHEN TO START ERT AND OTHER CONSIDERATIONS FOR OPTIMIZING TREATMENT OF FABRY DISEASE                                  | 160,522                               |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q1, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Jan 2016 – 31<sup>th</sup> Mar 2016

| Recipient Name(s) <sup>1</sup>  | Activity Title  | Funding Amount <sup>2</sup>           |
|---|---|---------------------------------------|
| National Association of Managed Care Physicians, Inc.   | EFFECTIVE A1C REDUCTION IN TYPE 2 DIABETES: A CLOSER LOOK AT COMBINATION INSULIN THERAPY  | 75,000                                |
| National Kidney Foundation, Inc.<br>University of Illinois at Chicago   | CKD-MBD: STATE-OF-THE-ART CONSIDERATIONS FOR OPTIMAL OUTCOMES   | 253,850                               |
| National Lipid Association  | NATIONAL LIPID ASSOCIATION 2016 MASTERS IN LIPIDOLOGY COURSE SERIES   | 20,000<br>Collaboration <sup>3</sup>  |
| National Lipid Association  | NATIONAL LIPID ASSOCIATION 2016 LIPID ACADEMY COURSE SERIES   | 20,000<br>Collaboration <sup>3</sup>  |
| Nebraska Academy of Physician Assistants.   | JOINT INJECTION WORKSHOP  | 5,100                                 |
| Nevada System of Higher Education<br>Foundation for Research and Education in Dermatology<br>North American Center for Continuing Medical Education, LLC<br>Horizon CME, Inc. | 2016 WINTER CLINICAL DERMATOLOGY CONFERENCE - HAWAII  | 50,000<br>Collaboration <sup>3</sup>  |
| NYU School of Medicine  | MEETING THE UNMET NEEDS OF PATIENTS WITH HYPERCHOLESTEROLEMIA: A FOCUS ON PCSK9 INHIBITORS  | 415,000<br>Collaboration <sup>3</sup> |
| NYU School of Medicine  | SEMINAR IN ADVANCED RHEUMATOLOGY  | 20,000<br>Collaboration <sup>3</sup>  |
| NYU School of Medicine  | 41ST ANNUAL COMPREHENSIVE REVIEW OF PHYSICAL MEDICINE AND REHABILITATION  | 5,000                                 |
| Pharmacy Times Office of Continuing Professional Education  | COST-EFFECTIVENESS OF DISEASE-MODIFYING THERAPIES IN MULTIPLE SCLEROSIS: A MANAGED CARE PERSPECTIVE   | 89,160                                |
| Pharmacy Times Office of Continuing Professional Education  | INNOVATION AND CLINICAL ADVANCES IN ACHIEVING GLYCEMIC CONTROL: EVALUATING THE EFFICACY OF COMPLIMENTARY AGENTS                               | 240,728                               |
| Pharmacy Times Office of Continuing Professional Education  | THE ROLE OF THE PHARMACIST IN ACHIEVING TIGHT GLYCEMIC CONTROL IN TYPE 2 DIABETES: PROMOTING PATIENT SELF-MONITORING AND AGGRESSIVE TREATMENT | 53,346                                |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q1, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Jan 2016 – 31<sup>th</sup> Mar 2016

| Recipient Name(s) <sup>1</sup>   | Activity Title  | Funding Amount <sup>2</sup> |
|--|---|-----------------------------|
| Physicians' Education Resource, LLC  | 2016 NEW YORK GU™: 9TH ANNUAL INTERDISCIPLINARY PROSTATE CANCER CONGRESS®   | 75,000                      |
| Postgraduate Healthcare Education, LLC   | OPTIMIZED APPROACHES TO INSULIN THERAPY AND GLUCOSE CONTROL IN TYPE 2 DIABETES  | 301,000                     |
| Postgraduate Institute for Medicine C-MEducation Resources, LLC                          | NEW THERAPEUTIC ADVANCES AND PRACTICAL STRATEGIES FOR COMPLEMENTARY BASAL INSULIN PLUS INCRETIN SYSTEM-TARGETED THERAPY TO OPTIMIZE GLUCOSE CONTROL | 309,500                     |
| Postgraduate Institute for Medicine C-MEducation Resources, LLC                          | NEW THERAPEUTIC ADVANCES AND PRACTICAL STRATEGIES FOR COMPLEMENTARY BASAL INSULIN PLUS INCRETIN SYSTEM-TARGETED THERAPY IN COMPLEX PATIENTS WITH    | 331,000                     |
| Primary Care Education Consortium  | COMBINING A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST WITH BASAL INSULIN: THE WHY AND HOW  | 309,985                     |
| PRIME Education Inc (PRIME)  | NEW TREATMENT GUIDELINES, EVIDENCE, AND AGENTS IN RHEUMATOID ARTHRITIS  | 249,505                     |
| Pri-Med Institute, LLC (d/b/a pmiCME)<br>Horizon CME, Inc.                               | HOW TO SELECT AND INITIATE INSULIN THERAPY IN THE TYPE 2 DIABETES PATIENT   | 998,500                     |
| Pri-Med Institute, LLC (d/b/a pmiCME)<br>Horizon CME, Inc.                               | GLP-1 RECEPTOR AGONISTS AND BASAL INSULIN COMBINATION: AN COMPLEMENTARY STRATEGY FOR TYPE 2 DIABETES TREATMENT INTENSIFICATION                      | 977,000                     |
| Projects In Knowledge, Inc.  | MEDIMAGE CASES: MULTIPLE SCLEROSIS  | 125,000                     |
| Rhode Island Hospital, CME   | ENDOCRINE GRAND ROUNDS  | 10,000                      |
| Rutgers, The State University of New Jersey<br>Global Academy for Medical Education, LLC | SKIN DISEASE EDUCATION FOUNDATION'S 40TH ANNUAL HAWAII DERMATOLOGY SEMINAR  | 10,000                      |
| ScientiaCME, LLC<br>Specialty Pharma Education Center                                    | PROSTATE CANCER: ADVANCES IN PATIENT MANAGEMENT & TREATMENT OPTIONS   | 14,875                      |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q1, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Jan 2016 – 31<sup>th</sup> Mar 2016

| Recipient Name(s) <sup>1</sup>   | Activity Title  | Funding Amount <sup>2</sup> |
|--|---|-----------------------------|
| Scripps Health   | SCRIPPS WHITTIER DIABETES INSTITUTE'S PROJECT DULCE   | 50,000                      |
| The Endocrine Society<br>Advanced Studies in Medicine                                    | THE EFFECTIVE USE OF INSULIN IN TYPE 2 DIABETES: A FOCUS ON TREATMENT ADVANCES  | 329,613                     |
| The Endocrine Society<br>Institute for Medical and Nursing Education                     | DIABETES MASTERS SERIES 2016: INITIATING THE CONVERSATION: SHARING PERSPECTIVES ON ADVANCES IN T2DM TREATMENT TO IMPROVE PATIENT-CENTERED CARE                                  | 237,055.5                   |
| The Endocrine Society<br>Scripps Health  | NEW COMPLEMENTARY INSULIN COMBINATIONS TO ACHIEVE HBA1C TARGETS: 2016 ENDOCRINE SOCIETY ANNUAL CONVENTION SATELLITE SYMPOSIUM   | 361,515                     |
| The Massachusetts General Hospital   | CLINICAL ENDOCRINOLOGY 2016   | 5,000                       |
| The Medical College of Wisconsin, Inc.<br>Paradigm Medical Communications, LLC           | NEW TERRITORY FOR THE UROLOGIST: OPTIMAL MONITORING AND TREATMENT SELECTION FOR MCRPC   | 150,000                     |
| The Medical College of Wisconsin, Inc.<br>PeerView Institute for Medical Education, Inc. | OPTIMIZING STEM CELL MOBILIZATION STRATEGIES TO ENHANCE SUCCESS OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION   | 299,980                     |
| The Vitamin D Workshop Inc.  | THE 19TH WORKSHOP ON VITAMIN D  | 5,000                       |
| Trustees of Boston University<br>Continuing Education Alliance, LLC                      | PCE DIRECTED LEARNING ECOURSE: A MULTIMODAL APPROACH TO MANAGING KNEE OSTEOARTHRITIS  | 152,105                     |
| Trustees of the University of Pennsylvania/CME   | 2016 THYROID MASTER CLASS: MANAGEMENT OF ADVANCED (PROGRESSIVE MEDULLARY AND RAI-REFRACTORY DIFFERENTIATED) THYROID CANCER AND UPDATE IN THYROID/PARATHYROID ULTRASOUND IMAGING | 10,000                      |
| University of Cincinnati<br>PeerView Institute for Medical Education, Inc.               | PEERVIEW INREVIEW, "ACHIEVING RAPID CONTROL OF DISEASE ACTIVITY IN PATIENTS WITH MULTIPLE SCLEROSIS: THE INCREASINGLY IMPORTANT ROLE OF DISEASE-MODIFYING"                      | 68,700                      |
| University of Massachusetts Medical School<br>C-MEducation Resources, LLC                | THE PHYSIOLOGIC BASIS FOR OPTIMIZING GLYCEMIC CONTROL WITH BASAL INSULIN IN COMPLEX PATIENTS WITH DIABETES  | 331,000                     |
| University of Massachusetts Medical School<br>C-MEducation Resources, LLC                | THE FOUNDATIONAL ROLE AND PHYSIOLOGIC BASIS FOR OPTIMIZING GLYCEMIC CONTROL WITH LONG-ACTING INSULINS: FOCUS ON THE SAFETY-EFFICACY PROFILES OF NEW                             | 305,600                     |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q1, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.



Sanofi US, A SANOFI COMPANY



## Independent Medical Education Grants

1<sup>st</sup> Jan 2016 – 31<sup>th</sup> Mar 2016

| Recipient Name(s) <sup>1</sup>  | Activity Title  | Funding Amount <sup>2</sup>           |
|---|---|---------------------------------------|
| University of Massachusetts Medical School<br>C-MEducation Resources, LLC | NEW FRONTIERS AND CLINICAL ADVANCES IN IMMUNOTHERAPY FOR ASTHMA: FOCUS ON BIOLOGICS-BASED MANAGEMENT OF MODERATE-TO-SEVERE ASTHMA IN PATIENTS | 389,000<br>Collaboration <sup>3</sup> |
| University of Virginia  | RENAL PHYSICIANS ASSOCIATION 2016 ANNUAL MEETING  | 25,000                                |
| University of Virginia  | RENAL PHYSICIANS ASSOCIATION ADVANCED PRACTITIONER CONFERENCE   | 7,500                                 |
| Yale University<br>Research To Practice                                   | CURRENT STRATEGIES AND ONGOING RESEARCH IN THE MANAGEMENT OF ADVANCED PROSTATE CANCER - AN INDEPENDENT SATELLITE SYMPOSIUM (ISS) HELD AS AN   | 80,000                                |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> “Funding Amount” is the amount that the Company funded during Q1, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2016 – 30<sup>th</sup> Jun 2016

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

| Recipient Name(s) <sup>1</sup>  | Activity Title  | Funding Amount <sup>2</sup>        |
|---|---|------------------------------------|
| Academic CME, LLC   | STRATEGIES FOR IMPROVING OUTCOMES IN PATIENTS WITH MULTIPLE SCLEROSIS   | 20,000                             |
| AKH Inc., Advancing Knowledge and Healthcare C-MEducation Resources, LLC                  | NOVEL MECHANISMS AND ADVANCING THERAPEUTIC PARADIGMS FOR OPTIMIZING REAL WORLD MANAGEMENT OF HYPERCHOLESTEROLEMIA: APPLYING LDL-TARGETED THERAPIES FOR CV RISK REDUCTION TO THE FRONT LINES OF CARDIOVASCULAR, DIABETES, AND INTERNAL MEDICINE PRACTICE | 350,000 Collaboration <sup>3</sup> |
| AKH Inc Advancing Knowledge and Healthcare C-MEducation Resources, LLC                    | NAVIGATING THE COMPLEX MAZE OF LDL-LOWERING THERAPIES: A REAL WORLD ROADMAP FOR THE CARDIOVASCULAR SPECIALIST   | 378,700 Collaboration <sup>3</sup> |
| American Academy of Physician Assistants  | AAPA CONFERENCE 2016 - ENDOCRINOLOGY TRACK  | 12,500                             |
| American Academy of Physician Assistants  | AAPA CONFERENCE 2016 - NEPHROLOGY TRACK   | 6,000                              |
| American Academy of Physician Assistants  | AAPA CONFERENCE 2016 - ORTHOPAEDICS TRACK   | 7,500                              |
| American Association of Clinical Endocrinologists   | AACE 25TH ANNUAL MEETING AND CLINICAL CONGRESS- DIABETES SESSIONS   | 5,000                              |
| American Association of Clinical Endocrinologists   | CALIFORNIA CHAPTER OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS PRESENTS: HOT TOPICS IN DIABETES AND ENDOCRINOLOGY FOR PRIMARY CARE 2016  | 20,000                             |
| American Association of Diabetes Educators<br>Institute for Medical and Nursing Education | AADE 2016: DOES THE SHOE FIT? MATCHING THE RIGHT INSULIN COMBINATION TO INDIVIDUAL PATIENTS WITH T2DM   | 321,194                            |
| American Association of Nurse Practitioners (AANP)<br>Medical Communications Media, Inc.  | SECONDARY PREVENTION OF ASCVD: NOVEL THERAPIES TO IMPROVE OUTCOMES IN PATIENTS WITH HYPERCHOLESTEROLEMIA  | 75000 Collaboration <sup>3</sup>   |
| American College of Allergy, Asthma & Immunology<br>Eastern Allergy Conference            | EAC 2016 - UPDATE IN ALLERGY, ASTHMA & IMMUNOLOGY   | 10,000 Collaboration <sup>3</sup>  |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2016 – 30<sup>th</sup> Jun 2016

| Recipient Name(s) <sup>1</sup>  | Activity Title  | Funding Amount <sup>2</sup>           |
|---|---|---------------------------------------|
| American Diabetes Association   | DIABETES IS PRIMARY   | 133,595                               |
| American Diabetes Association   | 31ST ANNUAL CLINICAL CONFERENCE ON DIABETES   | 32,000                                |
| American Society of Gene Therapy  | ASGCT 19TH ANNUAL MEETING   | 26,000                                |
| American Society of Health-System Pharmacists                               | THE CHANGING LANDSCAPE OF HYPERCHOLESTEROLEMIA: THE EMERGING ROLE OF NON-STATIN THERAPIES           | 117,215<br>Collaboration <sup>3</sup> |
| American Thoracic Society   | ATS 2016 INTERNATIONAL CONFERENCE - SELECTED SESSIONS IN ASTHMA                                     | 20,178<br>Collaboration <sup>3</sup>  |
| Baylor University Medical Center dba A. Webb Roberts Center<br>MedNet, LLC  | UPDATE ON GLP-1 RECEPTOR AGONISTS IN THE MANAGEMENT OF TYPE 2<br>DIABETES MELLITUS                  | 20,000                                |
| Carolinas Healthcare System/Charlotte AHEC                                  | 30TH ANNUAL MEETING OF THE GLOMERULAR DISEASE COLLABORATIVE NETWORK                                 | 3,000                                 |
| Children's Hospital Corporation   | BOSTON CHILDREN'S HOSPITAL, DIVISION OF NEPHROLOGY WEEKLY SEMINAR<br>SERIES                         | 5,500                                 |
| Consortium of Multiple Sclerosis Centers<br>Nurse Practitioner Alternatives | 2016 SCIENCE OF MS MANAGEMENT   | 69,225                                |
| Foundation of the Consortium of MS Centers                                  | 2016 MS MENTORSHIP FORUM  | 25,000                                |
| Horizon CME, Inc.   | GLP-1 RECEPTOR AGONISTS: AN ALTERNATIVE TO PRANDIAL INSULIN   | 265,190                               |
| Horizon CME, Inc.   | ACHIEVING LDL GOALS IN PATIENTS WITH HYPERCHOLESTEROLEMIA: APPLYING<br>PCSK9 INHIBITORS IN PRACTICE | 187,395<br>Collaboration <sup>3</sup> |
| Horizon CME, Inc.   | CURRENT THERAPIES FOR PROSTATE CANCER   | 24,000                                |
| Johns Hopkins University<br>Medical Communications Media, Inc.              | PATIENT-CENTERED CARE IN ADVANCED PROSTATE CANCER   | 60,000                                |
| Johns Hopkins University<br>Medical Logix, LLC                              | MULTIPLE SCLEROSIS IN THE AGE OF ENHANCED THERAPEUTIC OPTIONS                                       | 100,000                               |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.



## Independent Medical Education Grants

1<sup>st</sup> Apr 2016 – 30<sup>th</sup> Jun 2016

| Recipient Name(s) <sup>1</sup>  | Activity Title  | Funding Amount <sup>2</sup>           |
|---|---|---------------------------------------|
| Johns Hopkins University<br>Medscape, LLC   | REAL-LIFE SCENARIOS: SIMULATION IN MCRPC  | 50,000                                |
| Medical Education Resources<br>Tarsus Cardio Inc. dba Cardiometabolic Health Congress | PATIENT-FOCUSED LDL-C MANAGEMENT AND RISK REDUCTION IN CLINICAL PRACTICE: THE UTILITY OF PCSK9 INHIBITORS   | 200,000<br>Collaboration <sup>3</sup> |
| Med-IQ, LLC   | RECENT UPDATES IN CKD-MBD: MERGING SCIENCE AND PATIENT-CENTERED CARE  | 84,883                                |
| Med-IQ, LLC<br>Taking Control of Your Diabetes  | PRACTICAL STRATEGIES FOR ADVANCING INSULIN THERAPY: FROM TIMELY INITIATION AND APPROPRIATE TITRATION OF BASAL INSULIN TO ADDRESSING POST PRANDIAL GLUCOSE CONTROL | 995,246.5                             |
| Medscape, LLC   | KEY CONCEPTS IN CKD-MBD: ESSENTIALS FOR IMPROVING OUTCOMES  | 199,500                               |
| Medscape, LLC   | ADVANCES IN BASAL INSULIN   | 829,075                               |
| Medscape, LLC   | CME-TV: INDIVIDUALIZING T2D INSULIN THERAPY UTILIZING COMPLIMENTARY MECHANISMS OF ACTION  | 816,000                               |
| Medscape, LLC   | CASE CONSIDERATIONS: HOW TO REDUCE CV RISK IN DYSLIPIDEMIA?   | 225,100<br>Collaboration <sup>3</sup> |
| Medscape, LLC   | 2016 UPDATE: CLINICAL ADVANCEMENTS IN MODERATE TO SEVERE ATOPIC DERMATITIS  | 640,000<br>Collaboration <sup>3</sup> |
| Medscape, LLC   | WHAT DO WE KNOW ABOUT LDL-C?: A 2016 UPDATE   | 242,190<br>Collaboration <sup>3</sup> |
| Medscape, LLC   | A PATIENT JOURNEY THROUGH STATIN INTOLERANCE: WHAT HAVE WE LEARNED?   | 249,215<br>Collaboration <sup>3</sup> |
| Medscape, LLC   | AN ENDOCRINOLOGY CLINIC IN DYSLIPIDEMIA: SOLVING CHALLENGING CASES  | 237,915<br>Collaboration <sup>3</sup> |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2016 – 30<sup>th</sup> Jun 2016

| Recipient Name(s) <sup>1</sup>                               | Activity Title   | Funding Amount <sup>2</sup>            |
|--|--|--|
| Medscape, LLC  | RHEUMATOID ARTHRITIS: FOUNDATIONS IN PATHOPHYSIOLOGY, TARGETS, AND TREATMENT   | 249,825<br>Collaboration <sup>3</sup>  |
| Medscape, LLC  | WATERSHEDS IN RHEUMATOID ARTHRITIS: A CONCISE GUIDE TO MAJOR CONFERENCES IN 2016   | 99,500<br>Collaboration <sup>3</sup>   |
| Michigan State Medical Society                               | DIABETES AND LIPID UPDATES   | 5,000                                  |
| MidEastern Chapter of the Society of Nuclear Medicine        | 46TH ANNUAL SPRING MEETING AND EXHIBITION OF THE MIDEASTERN CHAPTER OF THE SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 7,500                                  |
| Missouri Academy of Physician Assistants                     | DIABETES UPDATE FOR THE PRIMARY CARE PROVIDER  | 5,000                                  |
| Montefiore Medical Center<br>PlatformQ Health Education, LLC | EVOLVING TREATMENT PARADIGMS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER  | 75,000                                 |
| National Association of Managed Care Physicians, Inc.        | BEST PRACTICES IN THE TREATMENT AND MANAGEMENT OF RELAPSING MULTIPLE SCLEROSIS   | 57,000                                 |
| National Association of Managed Care Physicians, Inc.        | ADVANCES IN LDL-C REDUCTION: A STRATEGIC LOOK AT THE EFFECTIVENESS OF PCSK9 INHIBITORS                                       | 25,000<br>Collaboration <sup>3</sup>   |
| National Comprehensive Cancer Network, Inc.                  | NCCN 2016 ONCOLOGY CASE MANAGER AND MEDICAL DIRECTOR PROGRAM   | 25,000                                 |
| National Comprehensive Cancer Network, Inc.                  | 2016-2017 MONTHLY ONCOLOGY TUMOR BOARDS: A MULTIDISCIPLINARY APPROACH TO INDIVIDUALIZED PATIENT CARE                         | 25,000                                 |
| National Jewish Health                                       | EVALUATION AND TREATMENT OF SEVERE ASTHMA: THE ROLE OF BIOLOGIC AND DIRECTED THERAPIES                                       | 94,011.5<br>Collaboration <sup>3</sup> |
| National Jewish Health<br>Prova Education, Inc               | ATOPIC DERMATITIS: DEFINING ITS PATHOGENESIS, TARGETING ITS TREATMENT  | 224,850<br>Collaboration <sup>3</sup>  |
| National Kidney Foundation, Inc.                             | PATHOGENESIS AND MANAGEMENT OF FABRY DISEASE   | 166,485                                |
| National MS Society Greater New England Chapter              | NEW HAMPSHIRE LIVING WELL WITH MS CONFERENCE   | 1,500                                  |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> “Funding Amount” is the amount that the Company funded during Q2, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2016 – 30<sup>th</sup> Jun 2016

| Recipient Name(s) <sup>1</sup>   | Activity Title  | Funding Amount <sup>2</sup>           |
|--|---|---------------------------------------|
| National Lipid Association   | TRANSLATION OF THE LDL RECEPTOR: A NATIONAL LIPID ASSOCIATION CORE CURRICULUM INTENSIVE PROGRAM   | 125,000<br>Collaboration <sup>3</sup> |
| New Jersey Academy of Family Physicians  | MANAGING T2DM IN SPECIAL POPULATIONS  | 6000                                  |
| North American Center for Continuing Medical Education, LLC                                | GRAND ROUNDS IN CARDIOLOGY: PCSK9 INHIBITORS WITHIN THE TARGETED TREATMENT APPROACH TO HYPERCHOLESTEROLEMIA                                       | 499,838<br>Collaboration <sup>3</sup> |
| Nurse Practitioner Alternatives<br>International Organization of Multiple Sclerosis Nurses | IMPROVING CARE IN MULTIPLE SCLEROSIS: A NURSING PERSPECTIVE   | 100,000                               |
| Nurse Practitioner Alternatives<br>International Organization of Multiple Sclerosis Nurses | MULTIPLE SCLEROSIS 2016: WHAT NURSES NEED TO KNOW   | 57,900                                |
| Nurse Practitioner Alternatives<br>International Organization of Multiple Sclerosis Nurses | 2016 MS COUNSELING POINTS:HIGHLIGHTING THE ROLE OF NURSES IN MULTIDISCIPLINARY MANAGEMENT OF MS   | 35,625                                |
| Oakstone Publishing, LLC<br>PeerVoice America Limited                                      | ADVANCEMENTS IN CARE FOR PATIENTS WITH HYPERCHOLESTEROLEMIA AND RESIDUAL CV RISK: EMERGING DATA, EVOLVING STRATEGIES                              | 29,725<br>Collaboration <sup>3</sup>  |
| Oregon Health & Science University Foundation  | ON THE HORIZON: UPDATES IN MULTIPLE SCLEROSIS   | 9,930                                 |
| Penn State University<br>i3 Health   | GUIDELINE UPDATES AND EVOLVING CLINICAL PARADIGMS IN DIFFERENTIATED THYROID CANCER  | 23,500                                |
| Penn State University<br>PeerView Institute for Medical Education, Inc.                    | PEERVIEW SELECT-A-SCENARIO LIVE: TRANSFORMING PROSTATE CANCER CARE IN A RAPIDLY EVOLVING TREATMENT LANDSCAPE                                      | 120,510                               |
| Penn State University<br>PeerView Institute for Medical Education, Inc.                    | PEERVIEW SELECT-A-SCENARIO LIVE: "CRITICAL DISCUSSIONS IN PROSTATE CANCER: HOW TO SELECT AND SEQUENCE THERAPIES THROUGHOUT THE DISEASE CONTINUUM" | 150,000                               |
| Pharmacy Times Office of Continuing Professional Education                                 | ACHIEVING GLYCEMIC CONTROL: PROMOTING PATIENT SELF-MONITORING AND EXPLORING INNOVATIVE TREATMENT STRATEGIES IN THE CONVENIENT CARE SETTING        | 57,000                                |
| Pharmacy Times Office of Continuing Professional Education                                 | MANAGING HYPERLIPIDEMIA: A NEW CHARGE FOR SPECIALTY PHARMACY WITH THE ADVENT OF PCSK9 INHIBITORS  | 32,000<br>Collaboration <sup>3</sup>  |
| Pharmacy Times Office of Continuing Professional Education                                 | OPTIMIZING TREATMENT REGIMENS FOR MS: THE PHARMACIST'S ROLE IN ADVANCING PATIENT CARE   | 35,000                                |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2016 – 30<sup>th</sup> Jun 2016

| Recipient Name(s) <sup>1</sup>                                     | Activity Title   | Funding Amount <sup>2</sup> |
|--|--|-----------------------------|
| Pharmacy Times Office of Continuing Professional Education         | MANAGING ATOPIC DERMATITIS: A PHARMACIST'S OPPORTUNITY TO INTERVENE  | 86,450                      |
|  | CANCER SUMMARIES AND COMMENTARIE: UPDATE FROM CHICAGO: ADVANCES IN THE TREATMENT OF GENITOURINARY CANCERS  | Collaboration <sup>3</sup>  |
| Physicians' Education Resource, LLC                                |  | 40,000                      |
| Pna Centers For Neurological Research                              | RRNMF COURSE ON POMPE'S DISEASE RECOGNITION AND THERAPY  | 25,000                      |
|  | THE CHANGING LANDSCAPE IN THE TREATMENT OF RHEUMATOID ARTHRITIS: AN UPDATE FOR PHARMACISTS   | 52,500                      |
| Postgraduate Healthcare Education, LLC                             |  | Collaboration <sup>3</sup>  |
|  | IQ&A INTERACTIVE DIABETES INTELLIGENCE ZONE: GLYCEMIC REGULATION THROUGH COMBINATION THERAPY--FOCUS ON SAFETY, CONVENIENCE, METABOLIC EFFECTS, HA1C CONTROL, AND EFFICACY OF COMBINATION BASAL INSULIN-GLP-1 RA REGIMENS FOR FPG AND PPG CONTROL | 191,000                     |
| Postgraduate Institute for Medicine<br>C-MEducation Resources, LLC |  |                             |
| Postgraduate Institute for Medicine<br>Enquiring Minds LLC         | WHY AREN'T THEY TAKING THEIR MEDS? PATIENT-CENTERED APPROACHES TO NON-ADHERENCE IN MS  | 33,000                      |
|  | REMOVING THE COMPLEXITY AND CONCERNS OF INSULIN MANAGEMENT IN TYPE 2 DIABETES, 4-HOUR WORKSHOPS TO BE HELD DURING THE METABOLIC AND ENDOCRINE DISEASE SUMMITS 2016   | 78,595                      |
| Primary Care Education Consortium                                  |  |                             |
| PRIME Education Inc (PRIME)  | PRACTICAL SKILLS IN MEDICATION MANAGEMENT WITH NEWER CHOLESTEROL THERAPIES: CAN WE ACHIEVE PATIENT AND MANAGED CARE HOMEOSTASIS?   | 415,000                     |
|  |  | Collaboration <sup>3</sup>  |
| PRIME Education Inc (PRIME)  | GME-CME ADVANCED PRACTICE SEMINAR IN MULTIPLE SCLEROSIS: FOCUSED TRAINING FOR EFFECTIVE INDIVIDUALIZED TREATMENT DECISION-MAKING   | 150,329                     |
| PRIME Education Inc (PRIME)  | RHEUMATOLOGY HOUSE CALLS - ENGAGING PATIENTS AND PROVIDERS IN RHEUMATOID ARTHRITIS COLLABORATIVE LEARNING  | 172,845                     |
|  |  | Collaboration <sup>3</sup>  |
| PRIME Education Inc (PRIME)  | NEW TARGETS IN THE THERAPEUTIC LANDSCAPE FOR ADULTS WITH ATOPIC DERMATITIS   | 291,095                     |
|  |  | Collaboration <sup>3</sup>  |
| Pri-Med Institute, LLC (d/b/a pmiCME)                              | OSTEOARTHRITIS OF THE KNEE: A MULTI-MODAL APPROACH TO PAIN MANAGEMENT  | 160,000                     |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2016 – 30<sup>th</sup> Jun 2016

| Recipient Name(s) <sup>1</sup>  | Activity Title  | Funding Amount <sup>2</sup>           |
|---|---|---------------------------------------|
| Pri-Med Institute, LLC (d/b/a pmiCME)<br>Purdue University  | HOW LOW DO YOU GO? CLINICAL UPDATES IN LOW-DENSITY LIPOPROTEIN-CHOLESTEROL MANAGEMENT   | 490,479<br>Collaboration <sup>3</sup> |
| Focus Medical Communications, LLC   | 2016 ARTHROS CITY ROUNDS SERIES   | 10,000<br>Collaboration <sup>3</sup>  |
| Research Foundation of SUNY   | MEASURING QUALITY OF LIFE (QOL) IN ESRD<br>YEAR IN REVIEW -- A FOUR-PART MULTI-TUMOR REGIONAL CME SYMPOSIA SERIES<br>FOCUSED ON THE APPLICATION OF EMERGING RESEARCH INFORMATION TO THE<br>CARE OF PATIENTS WITH COMMON CANCERS: GENITOURINARY CANCERS MODULE | 5,000                                 |
| Research To Practice<br>San Francisco Neurological Society<br>Association of California Neurologists Foundation | CALIFORNIA NEUROLOGY SOCIETY - UPDATES IN NEUROLOGY 2016  | 60,000                                |
| Scripps Health  | ANNUAL NEW APPROACHES TO OPTIMIZE REAL-WORLD DIABETES CARE: SPRING<br>CONFERENCE  | 50,000                                |
| Society for Urologic Nurses and Associates (SUNA)   | COMPETENCE IN ADVANCED PROSTATE CANCER REGIONAL ONS CHAPTER<br>NURSING FORUMS. DEVELOPING STRATEGIES FOR SEQUENCING AND COMBINING<br>THERAPIES: NURSING CONSIDERATIONS FOR IMPLEMENTING A TAILORED<br>TREATMENT APPROACH                                      | 30,000                                |
| Society of Nuclear Medicine<br>Southwestern Chapter of the Society of Nuclear Medicine                          | 61ST ANNUAL MEETING OF THE SOUTHWESTERN CHAPTER, SNMMI  | ,2000                                 |
| Swedish Medical Center Foundation   | SIXTH ANNUAL INTENSIVE UPDATE IN NEUROLOGY  | 3,000                                 |
| Texas A&M University System Health Science Center Coastal Be  | 12TH ANNUAL DIABETES CONFERENCE: 'DIABETES HEAD TO TOE'   | 10,000                                |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2016 – 30<sup>th</sup> Jun 2016

| Recipient Name(s) <sup>1</sup>   | Activity Title  | Funding Amount <sup>2</sup>           |
|--|---|---------------------------------------|
| The Endocrine Society  | ENDO 2016 GENZYME THYROID SESSIONS  | 100,000                               |
| The Omnia-Prova Education Collaborative, Inc.<br>Prova Education, Inc.                     | MANAGEMENT OF RA: GLOBAL OUTLOOK AND LATIN AMERICAN IMPLICATIONS  | 311,067<br>Collaboration <sup>3</sup> |
| Trustees of Boston University<br>Continuing Education Alliance, LLC                        | KEYS TO ACHIEVING OPTIMAL GLUCOSE CONTROL: EARLY INSULIN INITIATION AND CONTROL OF POSTPRANDIAL GLUCOSE   | 375,000                               |
| Trustees of Boston University<br>Continuing Education Alliance, LLC                        | IMPLEMENTING NEW THERAPIES FOR REFRACTORY DYSLIPIDEMIA: PRACTICAL CONSIDERATIONS FOR CLINICAL PRACTICE  | 350,000<br>Collaboration <sup>3</sup> |
| Ultimate Medical Academy, LLC dba Global Education Group<br>Integritas Communications, LLC | IMPROVING OUTCOMES IN SEVERE ASTHMA: A NEW ERA IN PRECISION MEDICINE  | 185,333<br>Collaboration <sup>3</sup> |
| UMA MLG, LLC   | COMPREHENSIVE DYSLIPIDEMIA MANAGEMENT: A VIRTUAL REALITY TOUR BEYOND STATIN MONOTHERAPY   | 249,825<br>Collaboration <sup>3</sup> |
| University of Chicago<br>Intelligent Medical Decisions, Inc.                               | INSIDE DYSLIPIDEMIA MANAGEMENT: IMPROVING RISK ASSESSMENT, REFERRALS AND LIPID GOAL ATTAINMENT FOR HIGH-RISK CV PATIENTS  | 285,734<br>Collaboration <sup>3</sup> |
| University of Cincinnati<br>Advances in Cosmetic and Medical Dermatology                   | INSPIRING SYSTEM IMPROVEMENT WITH DATA-DRIVEN EDUCATION   | 25,000<br>Collaboration <sup>3</sup>  |
| University of Kansas Endowment Association   | MAUIDERM NP+PA SUMMER 2016  | 15,000                                |
| University of Massachusetts Medical School<br>C-MEducation Resources, LLC                  | NEUROMUSCULAR REVIEW COURSE SERIES 2016   | 15,000                                |
| University of Rochester<br>Society of Investigative Dermatology                            | PIVOTAL TREATMENT ADVANCES IN BIOLOGIC THERAPY FOR ATOPIC DERMATITIS (AD): FOCUS ON THE IMMUNOPATHOBIOLOGY OF AD AND ROLE OF EVOLVING BIOLOGIC THERAPIES FOR OPTIMIZING OUTCOMES IN PATIENTS WITH MODERATE-TO-SEVERE AND TREATMENT-RESISTANT AD | 376,000<br>Collaboration <sup>3</sup> |
|  | 2016 SOCIETY FOR INVESTIGATIVE DERMATOLOGY ANNUAL MEETING   | 50,000<br>Collaboration <sup>3</sup>  |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q2, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Apr 2016 – 30<sup>th</sup> Jun 2016

| Recipient Name(s) <sup>1</sup>  | Activity Title  | Funding Amount <sup>2</sup> |
|---|---|-----------------------------|
| University of Southern California                                     | VAN DER MEULEN SYMPOSIUM: MULTIPLE SCLEROSIS UPDATE                         | 20,000                      |
| University of Tennessee<br>Advanced Studies in Medicine               | ONCOLOGY PHARMACY CONSULTS: UPDATES ON THE MANAGEMENT OF PROSTATE<br>CANCER | 45,000                      |
| University of Texas Health Science Center at San Antonio              | AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2016 REVIEW                    | 3,500                       |
| University of Vermont and State Agricultural College                  | NEW ENGLAND THYROID CONFERENCE  | 10,000                      |
| USF Health Professions Conferencing Corporation<br>CEConsultants, LLC | 13TH ANNUAL ROCKY MOUNTAIN METABOLIC SYNDROME SYMPOSIUM                     | 5,000                       |
| Wellmont Health System  | 14TH ANNUAL DIABETES SYMPOSIUM  | 4,000                       |
| Yale University   | INAUGURAL 1-95 INFILTRATIVE CARDIOMYOPATHY CONFERENCE                       | 5,000                       |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> “Funding Amount” is the amount that the Company funded during Q2, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.



Sanofi US, A SANOFI COMPANY



## Independent Medical Education Grants

1<sup>st</sup> July 2016 – 30<sup>th</sup> Sep 2016

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

| Recipient Name(s) <sup>1</sup>                        | Activity Title   | Funding Amount <sup>2</sup> |
|---|--|-----------------------------|
| American Association of Clinical Endocrinologists     | ORR-AACE 18TH ANNUAL MEETING   | 5,000                       |
| American Association of Clinical Endocrinologists     | MID ATLANTIC-AACE 14TH ANNUAL MEETING  | 2,500                       |
| American Association of Clinical Endocrinologists     | TEXAS-AACE ANNUAL MEETING & TEXAS ENDOCRINE SURGICAL SYMPOSIUM   | 5,000                       |
| American Association of Clinical Endocrinologists     | NEVADA AACE ENDOCRINOLOGY FOR THE NON ENDOCRINOLOGISTS AND ANNUAL MEETING  | 5,000                       |
| American Association of Clinical Endocrinologists     | NEVADA-AACE ENDOCRINOLOGY FOR THE NON ENDOCRINOLOGISTS AND ANNUAL MEETING  | 7,500                       |
| American Association of Nurse Practitioners (AANP)    | BEST PRACTICES IN ACHIEVING OPTIMAL A1C TARGETS AND POST PRANDIAL GLYCEMIC CONTROL   | 141,980                     |
| American Diabetes Association                         | 14TH ANNUAL PROFESSIONAL EDUCATION SYMPOSIUM, AN AFTERNOON WITH DIABETES EXPERTS: DIABETES DISTRESS, PHYSICAL ACTIVITY, MEDICATIONS, AND UPDATES TO THE STANDARDS. | 10,000                      |
| American Health Resources, Inc.                       | EXAMINING NEW OPTIONS IN THE MANAGEMENT OF INSULIN RESISTANT TYPE 2 DIABETES: A FOCUS ON BASAL INSULIN THERAPY   | 4,600                       |
| American Society for Blood and Marrow Transplantation | 2017 ASBMT/SANOFI NEW INVESTIGATOR AWARD   | 65,000                      |
| Antidote Education Company                            | MANAGING DIABETES IN OLDER POPULATIONS   | 50,000                      |
| California Academy of Physician Assistants            | MANAGEMENT OF OSTEOARTHRITIS IN THE PRIMARY SETTING  | 4,000                       |
| California Academy of Physician Assistants            | 2016 ANNUAL MEETING OF THE CALIFORNIA ACADEMY OF PHYSICIAN ASSISTANTS (CAPA): UPDATES IN TYPE 2 DIABETES CARE  | 4,000                       |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> “Funding Amount” is the amount that the Company funded during Q3, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.



## Independent Medical Education Grants

1<sup>st</sup> July 2016 – 30<sup>th</sup> Sep 2016

| Recipient Name(s) <sup>1</sup>  | Activity Title   | Funding Amount <sup>2</sup> |
|---|--|-----------------------------|
| Cardiovascular Research Foundation  | BEST MANAGEMENT FOR COMPLEX PATIENTS WITH COMPLEX DISEASE: THE NEXT FRONTIER BEYOND REVASCULARIZATION      | 58,100                      |
| Consortium of Multiple Sclerosis Centers<br>Nurse Practitioner Alternatives | 2016 CMSC ANNUAL MEETING SCIENTIFIC PROGRAM  | 25,000                      |
| Consortium of Multiple Sclerosis Centers<br>Nurse Practitioner Alternatives | MS AT THE CUTTING EDGE: A 5-PART WEBINAR SERIES  | 56,700                      |
| Dignity Health<br>MandatoryCE LLC   | 5TH ANNUAL ARIZONA DIABETES SYMPOSIUM  | 50,000                      |
| Dignity Health<br>MandatoryCE LLC   | 2016 ARKANSAS DIABETES SYMPOSIUM: FOCUS ON PREVENTION, CURRENT TREATMENTS, AND COMORBIDITIES               | 35,000                      |
| Elsevier Office of Continuing Medical Education<br>Academic CME, LLC        | ECTRIMS 2016: OPTIMALLY MANAGING PATIENTS WITH MULTIPLE SCLEROSIS THROUGH INDIVIDUALIZED TREATMENT OPTIONS | 85,000                      |
| Emory University  | 9TH WORLD CONGRESS ON PREVENTION OF DIABETES AND ITS COMPLICATIONS   | 50,000                      |
| Florida Academy of Physician Assistants                                     | EVALUATING KIDNEY DISEASE: KIDNEY KASES  | 5,000                       |
| Florida Academy of Physician Assistants                                     | JOINT INJECTIONS   | 5,500                       |
| Foundation for Orthopaedic Research and Education, Inc.                     | ORTHOPAEDICS FOR THE PRIMARY CARE PRACTITIONER & REHABILITATION THERAPIST                                  | 5,000                       |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> “Funding Amount” is the amount that the Company funded during Q3, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> July 2016 – 30<sup>th</sup> Sep 2016

| Recipient Name(s) <sup>1</sup>   | Activity Title  | Funding Amount <sup>2</sup>          |
|--|---|--------------------------------------|
| Horizon CME, Inc.  | GLP-1 RECEPTOR AGONIST AND BASAL INSULIN: AN EMERGING STANDARD FOR TYPE DIABETES TREATMENT  | 53,253                               |
| Horizon CME, Inc.  | ULTRALONG-ACTING BASAL INSULINS: WHERE DO THEY FIT?   | 53,253                               |
| Integritas Communications, LLC<br>Ultimate Medical Academy, LLC dba Global Education Group | CLINICAL UPDATES IN THE MANAGEMENT OF SEVERE ASTHMA: NEW STRATEGIES TO INDIVIDUALIZE LONG-TERM CARE   | 5,000<br>Collaboration <sup>3</sup>  |
| LeBonheur Children's Hospital  | BACK TO SCHOOL DIABETES CONFERENCE  | 3,828                                |
| Medical Education Resources<br>Tarsus Cardio Inc. dba Cardiometabolic Health Congress      | COMBINING GLP-1RAS WITH INSULIN TO IMPROVE GLUCOSE CONTROL  | 159,650                              |
| Medical Learning Institute, Inc.<br>PeerView Institute for Medical Education, Inc.         | PEERVIEW VIDEO INSESSION AT AAN 2016, "STAYING CURRENT WITH THE LATEST UPDATES ON APPROVED DISEASE-MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS MANAGEMENT: CLINICAL HIGHLIGHTS FROM VANCOUVER" | 131,530                              |
| Med-IQ, LLC  | SEQUENCING TREATMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: HOW TO MATCH PATIENTS TO THE RIGHT THERAPY  | 158,565                              |
| Med-IQ, LLC  | THE EVOLVING THERAPEUTIC LANDSCAPE FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS   | 88,759<br>Collaboration <sup>3</sup> |
| National Association for Continuing Education  | POSTPRANDIAL HYPERGLYCEMIA AND GLP-1 RECEPTOR AGONISTS: EFFECTIVE STRATEGIES TO ACHIEVE GOALS   | 150,000                              |
| National Association of Managed Care Physicians, Inc.                                      | NEW PERSPECTIVES AND EMERGING TREATMENT PARADIGMS IN THE MANAGEMENT OF RELAPSING MULTIPLE SCLEROSIS   | 57,000                               |
| National Association of Managed Care Physicians, Inc.                                      | CLINICAL ADVANCES IN ATOPIC DERMATITIS: NOVEL THERAPIES FOR IMPROVED PATIENT OUTCOMES   | 57,000                               |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q3, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> July 2016 – 30<sup>th</sup> Sep 2016

| Recipient Name(s) <sup>1</sup>  | Activity Title  | Funding Amount <sup>2</sup> |
|---|---|-----------------------------|
| National Association of Managed Care Physicians, Inc.                 | IMPROVING PATIENT OUTCOMES WITH INDIVIDUALIZED THERAPY IN THE MANAGEMENT OF TYPE 2 DIABETES         | 57,000                      |
| National Kidney Foundation, Inc.                                      | 25TH ANNUAL FELLOWS RESEARCH FORUM  | 3,500                       |
| National Kidney Foundation, Inc.<br>University of Illinois at Chicago | CHRONIC KIDNEY DISEASE-MINERAL BONE DISORDER: IMPLICATIONS FOR CARDIAC OUTCOMES                     | 149,420                     |
| National Medical Association  | STRATEGIES TO ACHIEVE BETTER CLINICAL OUTCOMES IN TYPE 2 DIABETES AND ITS THERAPEUTIC COMPLICATIONS | 200,000                     |
| Penn State University<br>Antidote Education Company                   | 16TH ANNUAL DIABETES SYMPOSIUM  | 15,000                      |
| Penn State University<br>Medical Communications Media, Inc.           | STRATEGIES FOR IMPROVING OUTCOMES IN PATIENTS WITH MS   | 15,000                      |
| Pennsylvania Society of Physician Assistants                          | NEW TREATMENT OPTIONS IN DIABETES MELLITUS  | 8,000                       |
| Potomac Center for Medical Education<br>Rockpointe Corporation        | EXPANDING DMD TREATMENT OPTIONS FOR PATIENTS WITH MS  | 205,000                     |
| Primary Care Network, Inc.<br>PlatformQ Health Education, LLC         | THE EVOLUTION OF BASAL INSULINS: ONE SMALL STEP OR A GIANT LEAP?                                    | 100,000                     |
| Projects In Knowledge<br>MedPage Today, LLC                           | NEUROLOGY MASTERY IN MULTIPLE SCLEROSIS   | 120,000                     |
| Regents of the University of California                               | 6TH ANNUAL UC IRVINE HEALTH NEUROMUSCULAR COLLOQUIUM  | 20,000                      |
| Regents of the University of Colorado                                 | PRACTICAL WAYS TO ACHIEVE TARGETS IN DIABETES CARE  | 200,000                     |
| Regents, University of California                                     | THE 4TH ANNUAL UCLA DIABETES SYMPOSIUM  | 10,000                      |
| Scripps Health  | ANNUAL NEW APPROACHES TO OPTIMIZE REAL-WORLD DIABETES CARE: FALL CONFERENCE AND ENDURING MATERIALS  | 70,000                      |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> “Funding Amount” is the amount that the Company funded during Q3, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.



Sanofi US, A SANOFI COMPANY



## Independent Medical Education Grants

1<sup>st</sup> July 2016 – 30<sup>th</sup> Sep 2016

| Recipient Name(s) <sup>1</sup>  | Activity Title  | Funding Amount <sup>2</sup> |
|---|---|-----------------------------|
| The Board of Trustees of the UA for the UA at Birmingham  | SPECIAL NEPHROLOGY RESEARCH AND TRAINING CENTER SYMPOSIUM - 11/9/15   | 15,000                      |
| The Medical College of Wisconsin, Inc.<br>American Society for Blood and Marrow Transplantation | 2016 ASBMT CLINICAL RESEARCH TRAINING COURSE  | 25,000                      |
| University of California, San Diego - Behavioral Diabetes Institute                             | PROMOTING BEHAVIOR CHANGE IN DIABETES: A SKILL BUILDING PROGRAM FOR HEALTH CARE PROFESSIONALS                                   | 50,000                      |
| University of California, San Diego<br>Taking Control of Your Diabetes                          | ADDRESSING THE NATURAL HISTORY OF TYPE 2 DIABETES: PRACTICAL APPROACHES TO CONTROLLING FASTING AND POST-PRANDIAL GLUCOSE LEVELS | 142,899                     |
| University of Cincinnati<br>Global Academy for Medical Education, LLC                           | THE METABOLIC & ENDOCRINE DISEASE SUMMIT (MEDS) 2016  | 25,000                      |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> “Funding Amount” is the amount that the Company funded during Q3, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Oct 2016 – 31<sup>th</sup> Dec 2016

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

| Recipient Name(s) <sup>1</sup>  | Activity Title  | Funding Amount <sup>2</sup>          |
|---|---|--------------------------------------|
| American Academy of Pas   | 2016 ADULT HOSPITAL MEDICINE BOOT CAMP  | 5,000                                |
| American Association of Clinical Endocrinologists                               | CALIFORNIA CHAPTER OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS (CA AACE) 16TH ANNUAL MEETING & SYMPOSIUM | 5,000                                |
| American Association of Clinical Endocrinologists                               | DIABETES DAY FOR PRIMARY CARE CLINICIANS ADVANCES IN DIABETES CARE  | 75,000                               |
| American College of Allergy, Asthma & Immunology                                | PLENARY SESSION: MODERN THERAPIES FOR ALLERGIC SKIN DISEASES  | 35,000<br>Collaboration <sup>3</sup> |
| American Health Resources, Inc.   | NEW COMPLEMENTARY COMBINATION THERAPY FOR DIABETES: FIXED DOSE BASAL INSULINS AND GLP-1 RECEPTOR AGONISTS             | 21,800                               |
| American Nephrology Nurses' Association   | IMPROVING PATIENT OUTCOMES IN CKD-MBD: INDIVIDUALIZED MANAGEMENT AND ENHANCED PATIENT ENGAGEMENT                      | 139,250                              |
| American Society of Nephrology  | CKD-MBD GUIDELINES: A CRITICAL APPRAISAL OF RECENT STUDIES  | 181,790                              |
| American Society of Transplantation   | AST FELLOWS SYMPOSIUM ON TRANSPLANTATION (2016)   | 35,000                               |
| American Thyroid Association, Inc.<br>University of Colorado School of Medicine | 3RD ANNUAL E. CHESTER RIDGWAY TRAINEE CONFERENCE  | 25,000                               |
| American Thyroid Association, Inc.<br>University of Colorado School of Medicine | 86TH ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION   | 50,000                               |
| American Urological Association   | ADVANCEMENTS IN UROLOGY 2017, AN AUA/JUA SYMPOSIUM  | 15,000                               |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q4, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.



Sanofi US, A SANOFI COMPANY



## Independent Medical Education Grants

1<sup>st</sup> Oct 2016 – 31<sup>th</sup> Dec 2016

| Recipient Name(s) <sup>1</sup>  | Activity Title  | Funding Amount <sup>2</sup>           |
|---|---|---------------------------------------|
| American Urological Association Education & Research, Inc.  | ADVANCED PROSTATE CANCER: MANAGING THE SPECTRUM OF THE DISEASE  | 60,000                                |
| Annenberg Center for Health Sciences at Eisenhower  | EXPERTPERSPECTIVES: SHIFTING PARADIGMS, EMERGING TREATMENTS IN MODERATE TO SEVERE ATOPIC DERMATITIS   | 224,355<br>Collaboration <sup>3</sup> |
| Annenberg Center for Health Sciences at Eisenhower<br>Postgraduate Institute for Medicine<br>Prime Medic  | DEVELOPMENT OF SPANISH LANGUAGE VERSION OF: ANIMATED MULTIPLE SCLEROSIS (MS) PATIENT AN ANIMATED PATIENT S GUIDE TO MS /ANIMADAS DE ESCLEROSIS MÚLTIPLE (EM) PACIENTE GUÍA DEL PACIENTES ANIMADA A EM | 75,000                                |
| Augusta University  | NEUROLOGY FOR THE NON-NEUROLOGIST   | 5,000                                 |
| AXIS Medical Education, Inc.  | AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION AND MOBILIZATION IN MULTIPLE MYELOMA: CURRENT DEBATE AND DEVELOPMENTS  | 74,580                                |
| Baylor Scott & White Health<br>Baylor University Medical Center dba A. Webb Roberts Center<br>MedNet, LLC | 3RD ANNUAL SYMPOSIUM ON INDIVIDUALIZED NOVEL DISEASE-MODIFYING TREATMENT OPTIONS FOR MULTIPLE SCLEROSIS   | 40,000                                |
| Baylor Scott & White Health<br>MedNet   | EMERGING BIOLOGICAL THERAPIES FOR ATOPIC DERMATITIS IN CHILDREN AND ADULTS  | 35,000<br>Collaboration <sup>3</sup>  |
| California Optometric Association   | FABRY DISEASE - OPHTHALMIC MANIFESTATIONS AND RECENT ADVANCES   | 9,650                                 |
| Cleveland Clinic Educational Foundation   | MULTIPLE SCLEROSIS CASE-BASED ONLINE MONOGRAPH  | 25,000                                |
| Clinical Care Options, LLC<br>Postgraduate Institute for Medicine   | NEW DIRECTIONS IN GU CANCERS: HIGHLIGHTS FROM THE 2017 GENITOURINARY CANCERS SYMPOSIUM  | 25,000                                |
| C-MEducation Resources, LLC<br>AKH Inc Advancing Knowledge and Healthcare                                 | NEW FRONTIERS AND PIVOTAL CLINICAL ADVANCES IN PATHOIMMUNOBIOLOGY OF ATOPIC DERMATITIS: THE TRANSLATIONAL PATH IN ATOPIC DERMATITIS AND IMPLICATIONS FOR DERMATOLOGY PRACTICE                         | 297,000<br>Collaboration <sup>3</sup> |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> “Funding Amount” is the amount that the Company funded during Q4, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Oct 2016 – 31<sup>th</sup> Dec 2016

| Recipient Name(s) <sup>1</sup>  | Activity Title   | Funding Amount <sup>2</sup>          |
|---|--|--------------------------------------|
| Consortium of Multiple Sclerosis Centers<br>Nurse Practitioner Alternatives       | ADDRESSING COMORBIDITIES IN THE DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH MULTIPLE SCLEROSIS: A RESOURCE GUIDE FOR CLINICIANS                          | 85,000                               |
| Consortium of Multiple Sclerosis Centers<br>Nurse Practitioner Alternatives       | CLINICAL CONSULT: CASES AND COMPREHENSIVE CARE IN MS   | 115,200                              |
| Consortium of Multiple Sclerosis Centers<br>Nurse Practitioner Alternatives       | MONITORING AND FOLLOW-UP IN MULTIPLE SCLEROSIS COMPREHENSIVE CARE  | 60,725                               |
| Continuing Education Alliance, LLC<br>Board of Regents for University of Nebraska | TARGETED THERAPIES IN MODERATE TO SEVERE ATOPIC DERMATITIS: EMERGING OPTIONS   | 92,550<br>Collaboration <sup>3</sup> |
| Creative Educational Concepts, Inc.   | ADVANCED PROSTATE CANCER: SEARCHING FOR OPTIMAL THERAPY SEQUENCE AND ASSESSING EMERGING TREATMENT OPTIONS  | 15,000                               |
| Delaware Academy of Physician Assistants Inc.                                     | MULTIPLE SCLEROSIS   | 2,200                                |
| Elsevier Office of Continuing Medical Education<br>Advanced Studies in Medicine   | CLINICAL ADVANCES IN RHEUMATOID ARTHRITIS: A FOCUS ON IMPROVING PATIENT OUTCOMES   | 350,000                              |
| Elsevier Office of Continuing Medical Education<br>Excerpta Medica                | SPOTLIGHT ON FABRY DISEASE: DIAGNOSIS, GENOTYPE-PHENOTYPE CORRELATION, AND MULTIDISCIPLINARY PATIENT CARE  | 200,000                              |
| Elsevier Office of Continuing Medical Education<br>Excerpta Medica BV             | ESMO2016: A THERAPEUTIC UPDATE ON THE MANAGEMENT OF PATIENTS WITH PROSTATE CANCER  | 90,000                               |
| Excel Continuing Education  | MULTIPLE SCLEROSIS: MANAGING THE DISEASE, ITS SYMPTOMS AND QUALITY OF LIFE (PART OF THE SOUTH FLORIDA NEUROLOGY SYMPOSIUM: IMPROVING PATIENT OUTCOMES) | 7,000                                |
| Excel Continuing Education  | NEW DIRECTIONS IN THE MANAGEMENT OF POMPE DISEASE  | 64,120                               |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q4, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Oct 2016 – 31<sup>th</sup> Dec 2016

| Recipient Name(s) <sup>1</sup>   | Activity Title  | Funding Amount <sup>2</sup>           |
|--|---|---------------------------------------|
| Florida Academy of Physician Assistants Inc.   | MULTIPLE SCLEROSIS  | 5,000                                 |
| Foundation of the Consortium of MS Centers   | 2016-2017 ROBERT LISAK, MD MEDICAL STUDENT RESEARCH SCHOLARSHIP   | 8,000                                 |
| Global Academy for Medical Education<br>Postgraduate Institute for Medicine<br>Rutgers, the State University | SKIN DISEASE EDUCATION FOUNDATION'S 17TH ANNUAL LAS VEGAS DERMATOLOGY SEMINAR FEATURING THE 13TH ANNUAL PSORIASIS FORUM           | 25,000<br>Collaboration <sup>3</sup>  |
| Global Academy for Medical Education<br>Rutgers Biomedical and Health Sciences                               | 16TH ANNUAL CARIBBEAN DERMATOLOGY SYMPOSIUM   | 20,000<br>Collaboration <sup>3</sup>  |
| Global Academy for Medical Education<br>University of Louisville Research Foundation                         | SKIN DISEASE EDUCATION FOUNDATION'S 41ST ANNUAL HAWAII DERMATOLOGY SEMINAR  | 50,000<br>Collaboration <sup>3</sup>  |
| Haymarket Medical Education  | BASAL INSULIN PLUS GLP-1 RAS: THERAPEUTIC SYNERGIES TO OPTIMIZE PATIENT OUTCOMES: 4 VIDEO "HOUSE CALLS" DISCUSSIONS AMONG EXPERTS | 146,788                               |
| Illinois Academy of Physician Assistants   | JOINT INJECTABLES   | 4,000                                 |
| Illinois Academy of Physician Assistants   | CHRONIC KIDNEY DISEASE  | 5,000                                 |
| Indiana Academy of Physician Assistants  | "WHAT IS CHRONIC KIDNEY DISEASE (CKD) AND END STAGE RENAL DISEASE (ESRD)?"  | 6,500                                 |
| Indiana Neurological Society<br>Indiana State Medical Association  | DEMYELINATING DISEASES: WHAT TO DO WHEN THE INSULATION BEGINS TO FRAY   | 5,000                                 |
| Integritas Communications<br>Global Education group  | LOOKING BENEATH THE SURFACE IN ATOPIC DERMATITIS: TARGETING IMMUNE DYSREGULATION AND DELIVERING COMPREHENSIVE CARE.               | 361,807<br>Collaboration <sup>3</sup> |
| Integritas Communications, LLC<br>UMA Education, Inc. dba Global Education Group                             | ATOPIC DERMATITIS: NEW PERSPECTIVES ON MANAGING A CHRONIC INFLAMMATORY DISEASE  | 267,480<br>Collaboration <sup>3</sup> |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q4, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.





Sanofi US, A SANOFI COMPANY



## Independent Medical Education Grants

1<sup>st</sup> Oct 2016 – 31<sup>th</sup> Dec 2016

| Recipient Name(s) <sup>1</sup>   | Activity Title   | Funding Amount <sup>2</sup>           |
|--|--|---------------------------------------|
| Integritas Communications, LLC<br>UMA Education, Inc. dba Global Education Group     | CLINICAL ADVANCES IN ATOPIC DERMATITIS: EXPERT INSIGHTS INTO NEW AND EMERGING THERAPIES  | 202,218<br>Collaboration <sup>3</sup> |
| Integritas Communications, LLC<br>UMA Education, Inc. dba Global Education Group     | CLINICAL UPDATES IN RHEUMATOID ARTHRITIS: NEW STRATEGIES TO TARGET REMISSION AND INDIVIDUALIZE COMPREHENSIVE CARE  | 249,900<br>Collaboration <sup>3</sup> |
| International Eczema Council<br>International Psoriasis Council                      | PSORIASIS AND ATOPIC DERMATITIS: TWO DISEASES OR ONE SPECTRUM?   | 100,000<br>Collaboration <sup>3</sup> |
| International Organization of MS Nurses<br>Nurse Practitioner Alternatives           | NP CONNECTIONS: THE ROLE OF THE NURSE PRACTITIONER IN MULTIPLE SCLEROSIS CARE  | 75,000                                |
| Kentucky Academy of Physician Assistants   | JOINT INJECTION WORKSHOP   | 5,000                                 |
| Medical Learning Institute Inc.<br>PVI Peerview Institute for Medical Education Inc. | PEERVIEW LIVE AT CMSC 2017, GUIDING PATIENTS THROUGH THE RISKS AND BENEFITS OF DISEASE-MODIFYING THERAPY: PATIENT STORIES OF SHARED DECISION-MAKING THROUGHOUT THE COURSE OF MULTIPLE SCLEROSIS    | 345,810                               |
| Medical Learning Institute Inc.<br>PVI Peerview Institute for Medical Education Inc. | PEERVIEW LIVE AT ACMG 2017 STRENGTHENING THE GENETICS-HEMATOLOGY PARTNERSHIP TO SHORTEN THE PATH TO DIAGNOSIS & TREATMENT OF GAUCHER DISEASE TYPE 1: A PATIENT STORY                               | 219,430                               |
| Medical Learning Institute Inc.<br>PVI, PeerView for Medical Education Inc.          | PEERVIEW VIDEO INPLAY NOVEL OPTIONS AND PATIENT PERSPECTIVES IN RHEUMATOID ARTHRITIS: INDIVIDUALIZING CARE FOR THERAPEUTIC SUCCESS   | 169,480<br>Collaboration <sup>3</sup> |
| Medical Learning Institute Inc.<br>PVI, PeerView Institute for Medical Education     | PEERVIEW VIDEO INREVIEW: ASSESSING THE COMPARATIVE EFFECTIVENESS OF DISEASE-MODIFYING THERAPIES: WHAT CAN BE LEARNED FROM HEAD-TO-HEAD CLINICAL TRIALS AND RECENT NUMBER-NEEDED-TO-TREAT ANALYSES? | 60,000                                |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q4, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Oct 2016 – 31<sup>th</sup> Dec 2016

| Recipient Name(s) <sup>1</sup>   | Activity Title  | Funding Amount <sup>2</sup>           |
|--|---|---------------------------------------|
| Medical Learning Institute, Inc.<br>PeerView Institute for Medical Education, Inc. | PEERVIEW IN REVIEW, "DELAYING DISABILITY PROGRESSION IN THE MULTIPLE SCLEROSIS PATIENT: WHAT CAN WE LEARN FROM AVAILABLE DATA ON APPROVED DISEASE-MODIFYING THERAPY?" | 106,800                               |
| Medical Learning Institute, Inc.<br>PeerView Institute for Medical Education, Inc. | PEERVIEW TALKS: HIGHLY EFFECTIVE DISEASE-MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS: WHEN AND IN WHOM SHOULD THEY BE USED?  | 65,000                                |
| Medical Learning Institute, Inc.<br>PeerView Institute for Medical Education, Inc. | NEW DEVELOPMENTS IN THE TREATMENT OF ATOPIC DERMATITIS: CLINICAL HIGHLIGHTS FROM VIENNA   | 156,480<br>Collaboration <sup>3</sup> |
| Med-IQ, LLC  | DIFFERENTIATING GAUCHER DISEASE FROM OTHER HEMATOLOGIC CONDITIONS: EVERY DAY COUNTS   | 290,043                               |
| Med-IQ, LLC  | LYSOSOMAL STORAGE DISEASES: NEWBORN SCREENING UPDATES AND IMPLICATIONS FOR LONG-TERM CARE   | 261,483                               |
| Med-IQ, LLC  | FABRY DISEASE : WHEN TO TREAT   | 100,000                               |
| Michigan State Medical Society   | CARING FOR PATIENTS WITH A FOCUS ON THE KIDNEYS   | 5,000                                 |
| MS Views And News Inc.   | 2016 NEUROLOGICAL ASPECTS OF MS AND BEYOND- SYMPOSIUM   | 17,500                                |
| MSWorld Inc.   | 2016 MSWORLD-HOSTED TALKS SERIES  | 35,000                                |
| National Association of Managed Care Physicians, Inc.                              | NEW HORIZONS IN THE TREATMENT AND MANAGEMENT OF MULTIPLE SCLEROSIS: BEST PRACTICES FOR IMPROVED PATIENT OUTCOMES  | 70,000                                |
| National Association of Managed Care Physicians, Inc.                              | NEW HORIZONS IN THE TREATMENT AND MANAGEMENT OF ATOPIC DERMATITIS (AD): HOW NOVEL THERAPIES ARE CHANGING THE TREATMENT PARADIGM                                       | 90,000<br>Collaboration <sup>3</sup>  |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q4, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Oct 2016 – 31<sup>th</sup> Dec 2016

| Recipient Name(s) <sup>1</sup>   | Activity Title  | Funding Amount <sup>2</sup>           |
|--|---|---------------------------------------|
| National Jewish Health   | THE 39TH ANNUAL NATIONAL JEWISH HEALTH PULMONARY & ALLERGY UPDATE   | 20,000<br>Collaboration <sup>3</sup>  |
| National Kidney Foundation   | 12TH ANNUAL JOINT MEETING OF THE UPSTATE AND WESTERN NEW YORK COUNCILS ON RENAL NUTRITION   | 7,500                                 |
| National Kidney Foundation   | STRATEGIES TO IMPROVE PATIENT OUTCOMES IN CKD-MBD MANAGEMENT  | 243,260                               |
| Neurologic Disease Foundation  | 21ST FALL MS SEMINAR -- OPTIMIZING MANAGEMENT OF MS   | 5,995                                 |
| New England Section American Urological Assn<br>American Urological Association Education and Research, Inc. | 85TH ANNUAL MEETING NEW ENGLAND SECTION OF THE AMERICAN UROLOGICAL ASSOCIATION  | 10,000                                |
| Not-For-Profit Hospital Corporation  | THYROID CANCER MANAGEMENT? AN OVERVIEW AND UPDATE OF NEW TREATMENT OPTIONS  | 2,750                                 |
| Not-For-Profit Hospital Corporation  | END STAGE RENAL DISEASE FOR THE NON-NEPHROLOGIST  | 1,910                                 |
| PeerVoice America Limited<br>Oakstone Publishing, LLC.   | EMERGING PARADIGMS IN ATOPIC DERMATITIS: TARGETING THE UNDERLYING PATHOLOGY   | 492,850<br>Collaboration <sup>3</sup> |
| Penn State College of Medicine<br>Research To Practice   | CASES FROM THE COMMUNITY: CLINICAL INVESTIGATORS PROVIDE THEIR PERSPECTIVES ON EMERGING RESEARCH AND ACTUAL PATIENTS WITH ADVANCED PROSTATE CANCER AN INDEPENDENT SATELLITE SYMPOSIUM (ISS) HELD AS A PREMIUM ANCILLARY EVENT DURING THE 2017 GENITOURINARY CANCERS SYMPOSIUM | 80,000                                |
| Penn State University  | PENN STATE HERSHEY CANCER INSTITUTE: CONTEMPORARY TOPICS IN THYROID CANCER  | 3,500                                 |
| Pennsylvania Society of Physician Assistants   | MULTIPLE SCLEROSIS: A PRIMARY CARE PERSPECTIVE  | 4,500                                 |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q4, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Oct 2016 – 31<sup>th</sup> Dec 2016

| Recipient Name(s) <sup>1</sup>   | Activity Title   | Funding Amount <sup>2</sup>          |
|--|--|--------------------------------------|
| Pharmacy Times Continuing Education  | AN AMERICAN JOURNAL OF MANAGED CARE SYMPOSIUM: APPLYING MANAGED CARE STRATEGIES TO THE ADVANCING LANDSCAPE OF MULTIPLE SCLEROSIS | 92,358                               |
| Pharmacy Times Office of Continuing Professional Education   | MANAGING ATOPIC DERMATITIS: A PHARMACIST'S OPPORTUNITY TO INTERVENE  | 23,200<br>Collaboration <sup>3</sup> |
| Postgraduate Institute for Medicine<br>Clinical Care Options, LLC  | BEST PRACTICES FOR MANAGING ADVERSE EVENTS ASSOCIATED WITH NOVEL THERAPIES FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES            | 40,000                               |
| Potomac Center for Medical Education<br>Rockpointe Corporation   | NOVEL INSIGHTS IN ATOPIC DERMATITIS: PATHWAYS, BIOMARKERS, AND PHENOTYPES FOR A TARGETED APPROACH                                | 469,900                              |
| President and Fellows of Harvard College<br>Beth Israel Deaconess Department of Medicine                     | DIABETES AND CARDIOMETABOLIC SYNDROME IN PRIMARY CARE  | 10,000                               |
| President and Fellows of Harvard College<br>Dana Farber Cancer Institute                                     | 18TH BIENNIAL HARVARD UROLOGIC CANCER COURSE   | 50,000                               |
| President and Fellows of Harvard College<br>Massachusetts Eye and Ear Infirmary Department of Otolaryngology | SURGERY OF THE THYROID AND PARATHYROID GLANDS  | 10,000                               |
| PRIME Education Inc. (PRIME)   | ADVANCING OUR UNDERSTANDING OF THE IMMUNOLOGY AND TREATMENT CONSIDERATIONS IN ATOPIC DERMATITIS                                  | 289,785                              |
| ProCE, Inc.<br>Wild Iris Medical Education, Inc.   | EVOLUTION OF MULTIPLE SCLEROSIS MANAGEMENT: PHARMACY'S ROLE  | 119,975                              |
| Purdue University<br>CiME LLC  | APPLYING EVIDENCE BASED MANAGEMENT STRATEGIES FOR PATIENTS WITH MS: AN EDUCATIONAL DATA CONTINUUM                                | 62,792                               |
| Regents, University of California  | FOURTH ANNUAL UCLA REVIEW OF CLINICAL NEUROLOGY  | 5,000                                |
| Rheumatology Nurses Society<br>American Academy of Continuing Medical Education, Inc.                        | RHEUMATOLOGY NURSES SOCIETY 2016 ANNUAL CONFERENCE   | 25,000                               |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q4, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.



Sanofi US, A SANOFI COMPANY



## Independent Medical Education Grants

1<sup>st</sup> Oct 2016 – 31<sup>th</sup> Dec 2016

| Recipient Name(s) <sup>1</sup>   | Activity Title  | Funding Amount <sup>2</sup>           |
|--|---|---------------------------------------|
| RMEI<br>Postgraduate Institute for Medicine  | A LEARNING PATHWAY IN ATOPIC DERMATITIS: ACHIEVING SUCCESS IN ASSESSMENT AND MANAGEMENT TO IMPROVE PATIENT OUTCOMES   | 989,750<br>Collaboration <sup>3</sup> |
| RMEI<br>The Omnia-Prova Education Collaborative (TOPEC)<br>Robert Michael Educational Institute, LLC | TARGETING THE CYTOKINE PATHWAY IN RA MANAGEMENT: IMPLICATIONS FOR NOVEL AND EMERGING IL-6 AGENTS  | 199,610<br>Collaboration <sup>3</sup> |
| Sanford Medical Center Fargo   | THE FUTURE OF ASTHMA MANAGEMENT: PRECISION THERAPY WITH EMERGING CYTOKINE INHIBITORS  | 212,340<br>Collaboration <sup>3</sup> |
| Sidney Kimmel Medical College at Thomas Jefferson University   | 2016 SANFORD HEALTH NEPHROLOGY, DIALYSIS, TRANSPLANT SYMPOSIUM  | 3,000                                 |
| Society of Urologic Nurses and Associates<br>Plexus Communications                                   | 5TH ANNUAL DIABETES SYMPOSIUM: NEW ADVANCES & TRENDS  | 10,000                                |
| Southern Alliance for Physician Specialties CME  | EMERGING PRACTICE PATTERNS FOR THE UROLOGY NURSE IN MANAGING PATIENTS WITH ADVANCED PROSTATE CANCER: CHALLENGES AND BEST PRACTICES WITH SYSTEMIC THERAPY                                | 50,000                                |
| Southern Salt, Water, and Kidney Club  | 40TH ANNUAL SOUTHEASTERN CONSORTIUM FOR DERMATOLOGY UPDATES IN PSORIASIS AND INFLAMMATORY DISORDERS   | 10,000<br>Collaboration <sup>3</sup>  |
| The Medical College of Wisconsin, Inc.<br>Carden Jennings Publishing Co., Ltd.                       | 57TH ANNUAL SCIENTIFIC MEETING  | 2,500                                 |
| Trustees of Boston University<br>Continuing Education Alliance                                       | 25TH ANNUAL PERSPECTIVES IN UROLOGY: POINT COUNTERPOINT (PCP 25)  | 15,000                                |
| Trustees of Boston University<br>Continuing Education Alliance, LLC                                  | 2016 PCE ONCOLOGY SYMPOSIA SERIES FOR ADVANCED PRACTICE PROVIDERS SPECIALIZED IN ONCOLOGY: CHOOSING INITIAL THERAPY FOR METASTATIC PROSTATE CANCER: A NEW DIRECTION                     | 150,000                               |
|  | PRACTICING CLINICIANS EXCHANGE (PCE)<br>2016 PRIMARY CARE SYMPOSIA SERIES 3 FOR<br>NURSE PRACTITIONERS & PHYSICIAN ASSISTANTS: RHEUMATOID ARTHRITIS: TREATING TO TARGET IN PRIMARY CARE | 50,000<br>Collaboration <sup>3</sup>  |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q4, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

## Independent Medical Education Grants

1<sup>st</sup> Oct 2016 – 31<sup>th</sup> Dec 2016

| Recipient Name(s) <sup>1</sup>  | Activity Title  | Funding Amount <sup>2</sup>                     |
|---|---|---|
| UMA Education, Inc. dba Global Education Group  | SCRATCHING BENEATH THE SURFACE OF ATOPIC DERMATITIS   | 25,000<br>Collaboration <sup>3</sup>            |
| UMA Education, Inc. dba Global Education Group<br>Applied Clinical Education<br>UMA MLG, LLC          | METASTATIC PROSTATE CANCER: CURRENT TRENDS AND FUTURE LANDSCAPE<br>MANAGING MODERATE-TO-SEVERE ATOPIC DERMATITIS IN ADULTS: PATHOLOGY-BASED, TARGETED THERAPIES | 53,000<br>169,430<br>Collaboration <sup>3</sup> |
| University of Cincinnati  | INNOVATIVE TECHNIQUES: THE KNEE COURSE 2016   | 5,000   |
| University of Cincinnati<br>CORE Medical Education, LLC.  | PRACTICE CHANGING ADVANCES: EXPANDING THE ATOPIC DERMATITIS ARMAMENTARIUM   | 112,825<br>Collaboration <sup>3</sup>           |
| University of Cincinnati<br>CORE Medical Education, LLC   | TYPE 2 DIABETES: MASTERING COMBINATION THERAPIES TO INDIVIDUALIZE AND OPTIMIZE OUTCOMES   | 42,825  |
| University of Cincinnati<br>Robert Michael Educational Institute, LLC                                 | TAILORING APPROACHES TO MANAGEMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS: WHAT'S NEW?   | 247,170<br>Collaboration <sup>3</sup>           |
| University of Nevada, Reno School of Medicine<br>Foundation for Research and Education in Dermatology | 2016 FALL CLINICAL DERMATOLOGY CONFERENCE   | 125,000<br>Collaboration <sup>3</sup>           |
| University of Tennessee<br>Advanced Studies in Medicine   | LYSIS CRISIS: PHARMACIST'S ROLE AND RESPONSIBILITY IN THE MANAGEMENT OF TUMOR LYSIS SYNDROME  | 70,000  |
| University of Vermont and State Agricultural College  | NORTHERN NEW ENGLAND NEUROLOGICAL SOCIETY ANNUAL MEETING  | 5,000   |
| WebMD Global LLC  | 2016 CLINICAL COURSE ON NEW DEVELOPMENTS IN ATOPIC DERMATITIS   | 144,200<br>Collaboration <sup>3</sup>           |
| World Allergy Organization  | WAO INTERNATIONAL SCIENTIFIC CONFERENCE 2016  | 30,000<br>Collaboration <sup>3</sup>            |

<sup>1</sup> Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report, but appear on other reports on this site.

<sup>2</sup> "Funding Amount" is the amount that the Company funded during Q4, 2016 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

<sup>3</sup> Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.